07:00 , Aug 13, 2012 |  BioCentury  |  Strategy

Merck's new mark in HIV

Merck & Co. Inc. may be positioning itself to compete in the HIV combination therapy market dominated by Gilead Sciences Inc. and ViiV Healthcare LLC , the joint venture of GlaxoSmithKline plc and Pfizer Inc....
07:00 , Apr 18, 2011 |  BC Week In Review  |  Company News

Ambrilia cancer, infectious, endocrine news

Ambrilia's board approved resolutions whereby the company will seek to terminate an order of protection from the Superior Court of Quebec and will file for bankruptcy under Canada's Bankruptcy and Insolvency Act. Raymond Chabot Grant...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Company News

Ambrilia, TaiMed deal

TaiMed received exclusive, worldwide rights from Ambrilia to develop, manufacture and commercialize protease inhibitor (PI) and integrase inhibitor programs for HIV/AIDS infection. Ambrilia received $250,000 up front and is eligible for up to $7.6 million...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Financial News

Ambrilia financial update

Ambrilia's securities will be delisted from the Toronto Stock Exchange on March 4 for failure to comply with listing requirements. Ambrilia Biopharma Inc. (TSX:AMB), Verdun, Quebec   Business: Cancer, Infectious, Endocrine   Date announced: 2/4/11...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Company News

Ambrilia cancer, infectious, endocrine news

Ambrilia said the Superior Court of Quebec extended to April 29, 2011, an order of protection from creditors. The extension gives the biotech time to develop and file a plan of arrangement for consideration by...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

Ambrilia cancer, infectious, endocrine news

Ambrilia said the Superior Court of Quebec extended to Jan. 28, 2011, from Sept. 30 an order of protection from creditors. The extension gives the biotech time to develop and file a plan of arrangement...
07:00 , May 31, 2010 |  BC Week In Review  |  Company News

Ambrilia cancer, infectious, endocrine news

Ambrilia said the Superior Court of Quebec extended to Sept. 30 from June 30 an order of protection from creditors, giving the biotech time to develop and file a plan of arrangement for consideration by...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Company News

Ambrilia cancer, infectious, endocrine news

Ambrilia announced that the Superior Court of Quebec extended to June 30 from April 13 an order of protection from creditors, giving the biotech time to develop and file a plan of arrangement for consideration...
08:00 , Feb 22, 2010 |  BC Week In Review  |  Company News

Ambrilia, SurModics deal

SurModics terminated a 2001 deal to develop and commercialize a sustained release formulation of octreotide claiming Ambrilia is in breach of contract. Ambrilia has denied the allegation. Further details of the termination were not disclosed....
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

Ambrilia cancer, infectious, endocrine news

Ambrilia announced that the Superior Court of Quebec extended to April 13, from Jan. 29, an order for protection from creditors, giving the biotech time to develop and file a plan of arrangement for consideration...